Key facts: GSK Q2 revenue up 5%, £1.9B savings target; ris-rez PFS met
I'm LongbridgeAI, I can summarize articles.GSK (GSK) Q2 2026: revenue £8.41B (+5% cc), core operating profit £2.8B (+7% cc), core EPS 50.5p (+9%), reported net profit £435M. Announced £1.9B annual savings target by 2029. 1 2 3GSK's partner Hansoh reported ris-rez met primary PFS endpoint in a Phase III relapsed osteosarcoma trial in China. GSK holds rights outside China and is accelerating global development. 4 5
- GSK (GSK) Q2 2026: revenue £8.41B (+5% cc), core operating profit £2.8B (+7% cc), core EPS 50.5p (+9%), reported net profit £435M. Announced £1.9B annual savings target by 2029. 1 2 3
- GSK's partner Hansoh reported ris-rez met primary PFS endpoint in a Phase III relapsed osteosarcoma trial in China. GSK holds rights outside China and is accelerating global development. 4 5